Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012-2021.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Country of Publication: Germany NLM ID: 8804297 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-4373 (Electronic) Linking ISSN: 09349723 NLM ISO Abbreviation: Eur J Clin Microbiol Infect Dis Subsets: MEDLINE
    • Publication Information:
      Publication: Berlin : Springer
      Original Publication: [Wiesbaden, Federal Republic of Germany] : Vieweg, [c1988-
    • Subject Terms:
      Urinary Tract Infections*/microbiology ; Urinary Tract Infections*/epidemiology ; Urinary Tract Infections*/drug therapy ; Escherichia coli Infections*/epidemiology ; Escherichia coli Infections*/microbiology ; Escherichia coli Infections*/drug therapy ; beta-Lactamases*/metabolism ; Escherichia coli*/isolation & purification ; Escherichia coli*/drug effects ; Escherichia coli*/genetics ; Escherichia coli*/enzymology; Humans ; Iceland/epidemiology ; Female ; Male ; Risk Factors ; Case-Control Studies ; Aged ; Middle Aged ; Prevalence ; Adult ; Adolescent ; Infant ; Child, Preschool ; Child ; Young Adult ; Aged, 80 and over ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Infant, Newborn
    • Abstract:
      Purpose: To investigate the association of potential risk factors for urinary tract infections (UTI) caused by E. coli producing ESBL vs. not producing ESBL in Iceland.
      Methods: Observational, case-control study including a cohort of 27,747 patients (22,800 females, 4,947 males; 1207 cases, 26,540 controls) of all ages with UTI caused by E. coli in 2012 to 2021 at the clinical microbiology laboratory covering about 2/3 of the Icelandic population. Clinical patient data was obtained from three national databases. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) as a measure of association between ESBL and exposure variables.
      Results: The proportion of samples with ESBL-producing E. coli increased during the study period, from 2.6% in 2012 to 7.6% in 2021 (p < 0.001). ESBL-positive strains were detected in 1207 individuals (4.4%), 905 females (4.0%) and 302 males (6.1%). The following risk factors were identified: Male sex, higher age, institution type (hospital, nursing home), hospital-associated UTI, Charlson comorbidity index score ≥ 3, history of cystitis or hospitalization in the past year, and prescriptions for certain antibiotics or proton pump inhibitors (PPIs: OR 1.51) in the past half year. The antibiotic associated with the highest risk was ciprofloxacin (OR 2.45).
      Conclusion: The prevalence of UTIs caused by ESBL-producing E. coli has been increasing in Iceland. The strongest risk factors for ESBL production were previous antibiotic use, especially ciprofloxacin, and previous PPI use, both considered to be overprescribed. It is important to promote the prudent use of these drugs.
      (© 2024. The Author(s).)
    • References:
      Gastrointest Endosc Clin N Am. 2020 Apr;30(2):239-251. (PMID: 32146944)
      Clin Infect Dis. 2017 Feb 1;64(3):361-363. (PMID: 27965302)
      Clin Microbiol Infect. 2021 Jun;27(6):871-877. (PMID: 32781243)
      Ann N Y Acad Sci. 2013 Jan;1277:84-90. (PMID: 23346859)
      Psychother Psychosom. 2022;91(1):8-35. (PMID: 34991091)
      Am J Infect Control. 2012 Mar;40(2):123-7. (PMID: 21775020)
      Curr Gastroenterol Rep. 2017 Sep;19(9):46. (PMID: 28780717)
      J Antimicrob Chemother. 2014 Feb;69(2):303-8. (PMID: 24068280)
      Clin Microbiol Rev. 2005 Oct;18(4):657-86. (PMID: 16223952)
      JAMA Netw Open. 2023 Feb 1;6(2):e230470. (PMID: 36821114)
      IJID Reg. 2022 May 04;3:278-286. (PMID: 35755476)
      J Antimicrob Chemother. 2017 Feb;72(2):582-588. (PMID: 27798205)
      Int J Infect Dis. 2017 Feb;55:16-19. (PMID: 27979787)
      Southeast Asian J Trop Med Public Health. 2016 Mar;47(2):227-33. (PMID: 27244961)
      Aging health. 2013 Oct;9(5):. (PMID: 24391677)
      Lancet. 2022 Feb 12;399(10325):629-655. (PMID: 35065702)
      J Infect. 2016 Feb;72(2):201-6. (PMID: 26702736)
      Clin Microbiol Infect. 2017 Dec;23(12):952-960. (PMID: 28377310)
      Clin Microbiol Infect. 2010 Feb;16(2):147-51. (PMID: 19689464)
      J Antimicrob Chemother. 2006 Apr;57(4):780-3. (PMID: 16492721)
      JAMA Intern Med. 2020 Apr 1;180(4):561-571. (PMID: 32091544)
      PLoS One. 2015 Jun 04;10(6):e0128004. (PMID: 26042842)
      Med Mal Infect. 2018 May;48(3):188-192. (PMID: 29054298)
      Eur J Clin Microbiol Infect Dis. 2004 Mar;23(3):163-7. (PMID: 14986159)
      JAC Antimicrob Resist. 2021 Jul 16;3(3):dlab092. (PMID: 34286272)
      J Antimicrob Chemother. 2016 Apr;71(4):1076-82. (PMID: 26755493)
      PLoS One. 2013 Jul 23;8(7):e69581. (PMID: 23936052)
      Infect Drug Resist. 2020 Nov 03;13:3945-3955. (PMID: 33177845)
    • Contributed Indexing:
      Keywords: Escherichia coli; Antibiotics; Antimicrobial agents; Antimicrobial resistance; Beta-lactamases; Risk factors; Urinary tract infections
    • Accession Number:
      EC 3.5.2.6 (beta-Lactamases)
      0 (Anti-Bacterial Agents)
    • Publication Date:
      Date Created: 20240627 Date Completed: 20240827 Latest Revision: 20240918
    • Publication Date:
      20240919
    • Accession Number:
      PMC11349795
    • Accession Number:
      10.1007/s10096-024-04882-z
    • Accession Number:
      38935227